Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA)

Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Profitability

This table compares Enveric Biosciences and TuHURA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-221.54%	-164.32%
TuHURA Biosciences	N/A	N/A	-152.88%

Analyst Recommendations

This is a summary of current recommendations and price targets for Enveric Biosciences and TuHURA Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	0	0	1	0	3.00
TuHURA Biosciences	0	0	2	1	3.33

Enveric Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 2,400.00%. TuHURA Biosciences has a consensus price target of $13.00, indicating a potential upside of 168.04%. Given Enveric Biosciences’ higher probable upside, analysts plainly believe Enveric Biosciences is more favorable than TuHURA Biosciences.

Insider and Institutional Ownership

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 3.2% of Enveric Biosciences shares are owned by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Enveric Biosciences and TuHURA Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$17.29 million	($2.56)	-0.16
TuHURA Biosciences	N/A	N/A	-$8.32 million	N/A	N/A

Volatility & Risk

Enveric Biosciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Summary

TuHURA Biosciences beats Enveric Biosciences on 7 of the 10 factors compared between the two stocks.

About Enveric Biosciences

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.